Conventional antipsychotic medications for schizophrenia

被引:141
|
作者
Dixon, LB
Lehman, AF
Levine, J
机构
[1] UNIV MARYLAND, CTR MENTAL HLTH SERV RES, BALTIMORE, MD 21201 USA
[2] NATHAN S KLINE INST PSYCHIAT RES, ORANGEBURG, NY 10962 USA
[3] NYU, SCH MED, NEW YORK, NY USA
关键词
D O I
10.1093/schbul/21.4.567
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
This article reviews the existing evidence for the efficacy and effectiveness of conventional antipsychotic medications in the treatment of schizophrenia. Among the issues reviewed are their efficacy for acute symptom episodes and. for long-term maintenance therapy, differential efficacy among medications, the gap between research-based efficacy rates;ind effectiveness rates in practice, dosing strategies, and the treatment of first-episode cases. Evidence for efficacy is overwhelming for reduction of positive symptoms but quite limited for other outcomes. Effectiveness in practice may be substantially less than efficacy in clinical trials, perhaps owing to patient heterogeneity, prescribing practices, and noncompliance. First-episode patients should be treated with antipsychotic medication, but perhaps at lower dosages, with consideration of a gradual decrease or discontinuation at 6 months to 1 year.
引用
收藏
页码:567 / 577
页数:11
相关论文
共 50 条
  • [31] Hospitalization risks in the treatment of schizophrenia - Comparison of antipsychotic medications
    Gianfrancesco, Frank
    Rajagopalan, Krithika
    Wang, Ruey-hua
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2006, 26 (04) : 401 - 404
  • [32] Use of depot antipsychotic medications for medication nonadherence in schizophrenia
    West, Joyce C.
    Marcus, Steven C.
    Wilk, Joshua
    Countis, Lisa M.
    Regier, Darrel A.
    Olfson, Mark
    SCHIZOPHRENIA BULLETIN, 2008, 34 (05) : 995 - 1001
  • [33] Efficacy of novel antipsychotic medications in schizophrenia recurrence prevention
    Sekiguchi, G
    Morokawa, Y
    Yuichi, I
    Atusi, O
    Nobumi, M
    Akimoto, T
    Suzuki, H
    Gen, K
    Makoto, K
    Noboru, Y
    Aoba, A
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (03) : A3 - A4
  • [34] Sexual dysfunctions induced by antipsychotic medications in patients with schizophrenia
    Tumuklu, Mevhibe N.
    Ulas, Halis
    Akdede, Berna Binnur Kivircik
    Alptekin, Koksal
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 19 : S27 - S31
  • [35] Effects of antipsychotic medications on sexual functioning in schizophrenia patients
    Keskin, N.
    Cakmak, S.
    Tamam, L.
    Evlice, Y. E.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S481 - S481
  • [36] Menstrual disturbance and galactorrhea in people taking conventional antipsychotic medications
    Thangavelu, Karthik
    Geetanjali, S.
    EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2006, 14 (04) : 459 - 460
  • [37] Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications
    Jerrell, JM
    SCHIZOPHRENIA BULLETIN, 2002, 28 (04) : 589 - 605
  • [38] Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
    Jaberi, Nayyer
    Faramarzi, Elnar
    Farahbakhsh, Mostafa
    Ostadarahimi, Alireza
    Jafarabadi, Mohammad Asghari
    Fakhari, Ali
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2020, 11 (03) : 310 - 314
  • [39] Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications
    Keefe, RSE
    Poe, MP
    McEvoy, JP
    Vaughan, A
    PSYCHOPHARMACOLOGY, 2003, 169 (3-4) : 383 - 389
  • [40] A global measure to assess switching antipsychotic medications in the treatment of schizophrenia
    Targum, Steven D.
    Pestreich, Linda
    Reksoprodjo, Petra
    Pereira, Heidi
    Guindon, Carrie
    Hochfeld, Marla
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2012, 27 (05) : 455 - 463